While it remains to be seen how the Trump administration deals with healthcare fraud, preventing fraudulent practices within your organization should be a priority-unless you want to be held personally liable.
You may remember last year Tenet Healthcare settling federal fraud charges related to Medicaid maternity claims at 2 hospitals. The agreement included a $513 settlement, an admission of guilt from the 2, and a non-prosecution agreement as long as the provider cooperated with ongoing investigations.
But you may not have seen the latest—the January indictment of a former Tenet senior vice president who was implicated in the scheme. John Holland could face up to 50 years in prison if convicted of federal charges of using bribery and kickbacks to steer Medicaid business to Tenet hospitals. Holland pleaded not guilty.
In a statement, Holland’s attorney denied the charges, saying the contracts in question were more than 10 years old, had been reviewed by multiple levels of the company, and that Holland didn’t benefit personally from the fraud. The feds filed forfeiture notices against 2 homes the former Tenet executive owns.
Going after individuals following corporate fraud investigations has been anticipated since a 2015 Department of Justice directive to focus more on individuals. The indictment of Holland follows a similar action against an Oklahoma official accused of taking kickbacks in exchange for giving out lucrative ambulance services contracts, according to an article in Bloomberg BNA's Health Care Daily Report.
Watch Your Claims and Your Payers Closely
What does this mean for you and your company? It means that you could be personally liable for the actions of others in your company, especially if you had the means to ferret out the fraud or the kickbacks yourself.
The data you need is there, within your claims. Analytics programs can show you aberrant patterns of claims, for example, doctors who are seeing high volumes of certain types of patients or writing large numbers of prescriptions for opioids or other controlled substances.
If your company contracts out services or issues procurement contracts, does one person have the final authority to say yes or no? Giving that type of power to one person can lead to abuse of that authority. You want dual authority, at least, or a committee to sign off on any contracts to keep everything aboveboard.
Regardless of how intricate the scheme, it seems that the bad guys get caught sooner or later. Don’t let yourself get caught up in someone else’s mess, especially when you had the means at hand to monitor the situation.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen